Phibro Animal Health (NASDAQ:PAHC) Cut to Hold at Zacks Research

Phibro Animal Health (NASDAQ:PAHC) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks reports.

Separately, Weiss Ratings raised shares of Phibro Animal Health from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, November 2nd. One investment analyst has rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $46.50.

Phibro Animal Health Price Performance

PAHC opened at $35.15 on Tuesday. The stock has a fifty day simple moving average of $36.89 and a two-hundred day simple moving average of $40.93. The company has a current ratio of 3.20, a quick ratio of 1.28 and a debt-to-equity ratio of 1.70. The company has a market cap of $1.43 billion, a price-to-earnings ratio of 10.59 and a beta of 0.42. Phibro Animal Health has a 12-month low of $28.25 and a 12-month high of $60.08.

Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Wednesday, November 4th. The company reported $0.79 EPS for the quarter, beating analysts’ consensus estimates of $0.78 by $0.01. The firm had revenue of $386.77 million for the quarter, compared to analysts’ expectations of $382.42 million. Phibro Animal Health had a net margin of 6.66% and a return on equity of 35.88%. Research analysts predict that Phibro Animal Health will post 3.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Phibro Animal Health

A number of institutional investors have recently modified their holdings of PAHC. Renaissance Technologies LLC increased its holdings in shares of Phibro Animal Health by 5.8% during the first quarter. Renaissance Technologies LLC now owns 576,735 shares of the company’s stock valued at $31,899,000 after acquiring an additional 31,435 shares in the last quarter. Advisors Asset Management Inc. bought a new position in Phibro Animal Health in the 3rd quarter worth about $20,546,000. Dimensional Fund Advisors LP grew its position in Phibro Animal Health by 3.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 507,852 shares of the company’s stock valued at $28,086,000 after purchasing an additional 15,517 shares during the last quarter. Boston Partners purchased a new stake in Phibro Animal Health during the 3rd quarter valued at about $10,907,000. Finally, Ranger Investment Management L.P. purchased a new stake in Phibro Animal Health during the 2nd quarter valued at about $9,182,000. 99.34% of the stock is owned by hedge funds and other institutional investors.

About Phibro Animal Health

Phibro Animal Health Corporation develops and markets products for animal health and nutrition. Its portfolio includes vaccines, medicated feed additives, and nutritional specialty products designed to support the health and productivity of livestock and other animals. The company also supplies trace minerals and related products used in animal nutrition and other applications. Its products serve markets including poultry, cattle, swine, and aquaculture, and are sold to customers in the United States and internationally.